AtriCure, Inc. (ATRC)

From the record

AtriCure, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

AtriCure, Inc.'s 10 filed years say what it did: revenue went from $155 million in fiscal 2016 to $535 million in fiscal 2025, up 14.7% a year; it rose in 8 of 9 years; the deepest fall was 11% from fiscal 2019 to fiscal 2020; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, AtriCure, Inc.'s diluted share count grew about 1.4% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 19 sales (4 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-10 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, AtriCure, Inc. lost about 2 cents for every dollar of shareholders' money, and gross profitability: its products earned about 61 cents per dollar of everything the company owns. Leverage: it owed about 25 cents per dollar of assets, and net share issuance: its share count grew 1.7% over the year (the filed statements).

From the record

AtriCure, Inc.'s standing among 109 graded names in its industry family: revenue of $535 million in fiscal 2025 ranks in the top 27% by size; a net margin of -2.1% ranks in the top 33%; revenue growth of 17.4% a year over the last 3 filed years ranks in the top 43% (its annual reports).

From the record

AtriCure, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Carrel, Michael H (President, CEO, & Director, as filed), filing under that title since 2012-11-05, 14 years (top 6% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 9.6 years (top 11%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

AtriCure, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $167 million against debt of $62 million leaves 16.1% of its assets as net cash, top 42% of its family; cash from operations less capital spending is 9% of revenue (top 24%); a gross margin of 75% (top 22%); research spending of 18.6% of revenue (top 42%) (its annual report).

From the record

AtriCure, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 17.4% a year over the last three filed years against 14.7% over all 10, speeding up (top 25% of its family); the newest year grew 14.9% (top 46%); research spending grew 20% a year (top 23%); capital spending grew -18.8% a year (bottom 30%) (its annual reports). AtriCure, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

AtriCure, Inc.'s newest year against its own record: revenue of $535 million in fiscal 2025 came in 3.2% below the $552 million its prior three years' pace pointed to (top 50% of its family); net income of $11 million against a prior three-year average of $41 million (top 25%); a net margin of -2.1% against -10.4% before (bottom 49%) (its annual reports).